Biotech · Private company
LIB Therapeutics LLC
Track this companyFree. Adds LIB Therapeutics LLC to your Dealase workspace and tells you when its record changes.
Clinical trials101 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- alirocumabPhase 3 · HypercholesterolemiaClinicalTrials.gov · fetched Nov 12, 2026
- evolocumabPhase 3 · Homozygous Familial HypercholesterolemiaClinicalTrials.gov · fetched Nov 12, 2026
- evolocumabPhase 3 · HypercholesterolemiaClinicalTrials.gov · fetched Nov 12, 2026
- lerodalcibepPhase 3 · Cardiovascular Risk FactorClinicalTrials.gov · fetched Nov 12, 2026
- lerodalcibepPhase 3 · Cardiovascular Disease With Mention of ArteriosclerosisClinicalTrials.gov · fetched Nov 12, 2026
- lerodalcibepPhase 3 · Cardiovascular DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- lerodalcibepPhase 3 · Heterozygous Familial HypercholesterolemiaClinicalTrials.gov · fetched Nov 12, 2026
- lerodalcibepPhase 3 · Homozygous Familial HypercholesterolemiaClinicalTrials.gov · fetched Nov 12, 2026
- lerodalcibepPhase 3 · HypercholesterolemiaClinicalTrials.gov · fetched Nov 12, 2026
- lerodalcibep 300 mg Monthly SCPhase 3 · Familial Hypercholesterolemia - HeterozygousClinicalTrials.gov · fetched Nov 12, 2026
- LIB003Phase 2 · LDL CholesterolClinicalTrials.gov · fetched Nov 12, 2026
- LIB003Phase 2 · HypercholesterolemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FHPHASE3 · ENROLLING_BY_INVITATION · started Jul 20, 2026ClinicalTrials.gov NCT07102511 · fetched Nov 12, 2026
- Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug ProductPHASE3 · COMPLETED · started Jan 28, 2022ClinicalTrials.gov NCT05234775 · fetched Nov 12, 2026
- Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C ReductionPHASE3 · UNKNOWN · started Apr 22, 2021ClinicalTrials.gov NCT04806893 · fetched Nov 12, 2026
- Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C ReductionPHASE3 · UNKNOWN · started Apr 22, 2021ClinicalTrials.gov NCT04797247 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C ReductionPHASE3 · COMPLETED · started Apr 22, 2021ClinicalTrials.gov NCT04797104 · fetched Nov 12, 2026
- Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD PatientsPHASE3 · COMPLETED · started Apr 22, 2021ClinicalTrials.gov NCT04790513 · fetched Nov 12, 2026
- Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C ReductionPHASE3 · UNKNOWN · started Dec 3, 2020ClinicalTrials.gov NCT04798430 · fetched Nov 12, 2026
- Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFHPHASE3 · COMPLETED · started Dec 7, 2019ClinicalTrials.gov NCT04034485 · fetched Nov 12, 2026
- Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003PHASE2 · COMPLETED · started Feb 14, 2019ClinicalTrials.gov NCT03847974 · fetched Nov 12, 2026
- Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C ReductionPHASE2 · COMPLETED · started May 22, 2018ClinicalTrials.gov NCT03549260 · fetched Nov 12, 2026